

Name: **MUHAMMAD KASHIF RIAZ**
Office Address: Vontz Center for Molecular Studies, Room 1320
1325 Eden Avenue, ML 0562
Cincinnati, OH 45267-0562, USA
Telephone: (513) 558-2104
Fax: (513) 558-2124
Cell: (513) 827-8313
Email: riazmk@ucmail.uc.edu

EDUCATION:

<i>Year</i>	<i>Degree</i>	<i>Field of Study</i>	<i>Institution</i>
1999 – 2005	MBBS / MD	Medicine	University of Health Sciences, Lahore, Pakistan

POST GRADUATE TRAINING:

<i>Year</i>	<i>Title</i>	<i>Specialty</i>	<i>Institution</i>
2005 - 2006	House Officer	Medicine/Surgery	Mayo Hospital, Lahore, Pakistan
2009 - 2010	Intern	Medicine	Shaukat Khanum Hospital, Lahore, Pakistan
2011 - 2014	Residency	Internal Medicine	The Jewish Hospital, Cincinnati, OH
2014 - 2017	Fellowship	Hematology/Oncology	University of Cincinnati, Cincinnati, OH

FACULTY ACADEMIC APPOINTMENTS:

<i>Year</i>	<i>Academic Title</i>	<i>Department</i>	<i>Institution</i>
2016 - 2017	Chief Fellow	Hematology/Oncology	University of Cincinnati
2017- Present	Assistant Professor	Hematology/Oncology	University of Cincinnati
2019- Present	Assistant Professor (Adjunct)	Hematology/Oncology	Veterans Affairs Medical Center, Cincinnati
2019- Present	Associate Program Director, Fellowship	Hematology/Oncology	University of Cincinnati

ADMINISTRATIVE/LEADERSHIP POSITIONS:

<i>Year</i>	<i>Position / Title</i>	<i>Department</i>	<i>Institution</i>
2018 - 2020	Head & Neck Cancer Clinical Trials Leader	Clinical Research Office	University of Cincinnati, Barrett Cancer Center
2019 - Present	Associate Program Directory, Hematology/Oncology Fellowship	Hematology/Oncology	University of Cincinnati, Cincinnati, OH

APPOINTMENTS AT HOSPITALS AND AFFILIATED INSTITUTIONS:

<i>Year</i>	<i>Position/Title</i>	<i>Department</i>	<i>Institution</i>
2015 - 2017	Hospitalist Physician	Internal Medicine	The Jewish Hospital, Cincinnati, OH
2017 - Present	Staff Physician	Hematology/Oncology	University of Cincinnati
2019 - Present	Adjunct Physician	Hematology/Oncology	Veterans Affairs Medical Center, Cincinnati, OH

BOARD CERTIFICATIONS:

<i>Year</i>	<i>Certification</i>
2014 - Present	Diplomat American Board of Internal Medicine
2017 - Present	Diplomat American Board of Hematology
2017 - Present	Diplomat American Board of Medical Oncology

PROFESSIONAL SOCIETIES:

<i>Year</i>	<i>Society Name</i>
2011	American College of Physicians (ACP)
2013	American Federation for Medical Research (AFMR)
2014	American Society of Hematology (ASH)
2014	American Society of Clinical Oncology (ASCO)
2015	International Association for the Study of Lung Cancer (IASLC)

PEER-REVIEWED PUBLICATIONS:

1	<i>High factor XI, recurrent pregnancy loss, enoxaparin.</i> CJ Glueck, J Pranikoff, N Khan, MK Riaz , K Chavan, P Raj, M Umar. <i>Fertility and sterility</i> 94 (7), 2828-2831
2	<i>Titration of lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels > 500 mg/dl despite conventional triglyceride lowering therapy</i> CJ Glueck, N Khan, MK Riaz , J Padda, Z Khan, P Wang <i>Lipids in health and disease</i> 11 (1), 143
3	<i>Testosterone, thrombophilia, and thrombosis</i> CJ Glueck, C Richardson-Royer, R Schultz, T Burger, F Labitue, MK Riaz , et al. <i>Clinical and Applied Thrombosis/Hemostasis</i> 20 (1), 22-30
4	<i>Ocular Thrombosis: An Uncommon Thrombotic Manifestation of Undiagnosed Factor V Leiden Heterozygosity</i> NB Gandhi, MK Riaz , P Wang, CJ Glueck <i>Investigative Ophthalmology & Visual Science</i> 55 (13), 4341-4341
5	<i>Recombinant Porcine Factor VIII, Obi-1, Successfully Controlled Gastrointestinal Bleeding in a Patient with Acquired Hemophilia A</i> MK Riaz , S Girnius, JE Palascak <i>Blood</i> 126 (23), 4676-4676
6	<i>The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer</i> MK Riaz , S Bal, T Wise-Draper <i>Journal of surgical oncology</i> 114 (3), 323-328
7	<i>A phase I dose-finding study of metformin in combination with concurrent cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma.</i> S Gulati, B Yaniv, S Palackdharry, V Takiar, ML Mierzwa, MK Riaz , ... <i>Journal of Clinical Oncology</i> 36 (15_suppl), 6074-6074
8	<i>Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN-004</i> LK Mell, PA Torres-Saavedra, SJ Wong, S Chang, JA Kish, A Minn, MK Riaz , ... <i>Journal of Clinical Oncology</i> 37 (15_suppl), 6065-6065
9	<i>Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.</i> S Gulati, J Desai, S Palackdharry, J Morris, Z Zhu, R Jandarov, MK Riaz , ... <i>Cancer</i> 2020, Vol 126 Issue2 (p354-362)

ABSTRACTS / NON-PEER-REVIEWED PUBLICATIONS:

1	<p><i>T-786 C Polymorphism of the Endothelial Nitric Oxide Synthase gene and Neuralgia-inducing cavitation Osteonecrosis of the jaws.</i> NA Khan, W Ahmed, MK Riaz, I Naqvi, AA Khan, M Juyal, CJ Glueck Journal of investigative medicine 58 (4), 674-674</p>
2	<p><i>Thrombophilic hyperhomocysteinemia, retinal vein and artery occlusion, and non-arteritic ischemic optic neuropathy.</i> M Umar, CJ Glueck, N Khan, MK Riaz, AA Khan, R Hutchins, P Wang Journal of investigative medicine 58 (4), 646-646</p>
3	<p><i>Prevention of pregnancy loss and pregnancy outcomes in women with polycystic ovary syndrome and familial thrombophilia by Glucophage and enoxaparin.</i> C Abuchaibe, Z Khan, N Goldenberg, C Glueck, J Pranikoff, P Wang, MK Riaz ... Journal of investigative medicine 60 (4), 721-721</p>
4	<p><i>Deep venous thrombosis, pulmonary embolism and osteonecrosis after starting exogenous testosterone therapy in men and women with previously undiagnosed thrombophilia ...</i> MK Riaz, CJ Glueck, J Padda, C Richardson-Royer, A Valdes, D Bowe, ... Journal of investigative medicine 61 (4), 794-794</p>
5	<p><i>Thrombophilia and hypofibrinolysis: Treatable etiologies of osteonecrosis of the knee</i> MK Riaz, G Boriel, CJ Glueck, RA Freiberg, MK Riaz, RA Freiberg, ... Journal of investigative medicine 61 (4), 774-775</p>
6	<p><i>Outcomes in patients with head and neck squamous cell carcinoma (HNSCC) requiring salvage resection after definitive therapy.</i> S Haque, MK Riaz, S Hassan, V Karivedu, J Ying, V Takiar, ... Journal of Clinical Oncology 35 (15_suppl), e17572-e17572</p>
7	<p><i>Retrospective review of four days of Von Willebrand's factor as surgical prophylaxis in Von Willebrand's disease.</i> S Bal, MK Riaz, D Peters, J Palascak, S Girnius Haematologica 102, 401-402</p>
8	<p><i>Unclear Clinical Course and Treatment Options for Clear Cell Lung Cancer: A Case Series</i> MK Riaz, D Mosko, J Wang, NA Karim Journal of thoracic oncology 10 (9), S690-S690</p>
9	<p><i>1122P Interim analysis of a single arm phase II study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.</i> T Wise-Draper, S Haque, A Steele, S Desai, T Harris, MK Riaz, JC Morris, ... Annals of Oncology 30 (Supplement_5), mdz252. 014</p>

CLINICAL TRIALS / RESEARCH ACTIVITIES: (ongoing)

1	A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects with HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC): Role: PI
2	A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation. Role: PI
3	A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination with Cetuximab in Patients with Advanced Head and Neck Squamous Cell Carcinoma: Role: Sub-I
4	UCCI-HN-1501: Phase II investigation of adjuvant combined Cisplatin and Radiation with Pembrolizumab in resected HNSCC. Role: Sub-I
5	UCCI-HN-1701: A Single Arm Phase 2 Study of Adjuvant Nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy. Role: Sub-I
6	UCCI-HN-1702: An open-label, phase II study of Durvalumab (MEDI4736) in combination with Cetuximab in previously treated/ metastatic Head and Neck Squamous Cell Carcinoma. Role: Sub-I
7	RTOG 10-08: A Randomized Phase II/Phase III Study Of Adjuvant Concurrent Radiation And Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors. Role: Sub-I
8	NRG HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin. Role: Sub-I
9	ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial, A151216. Role: Sub-I
10	PROSPER: A Phase 3 Randomized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy. Role: Sub-I

CLINICAL TRIALS / RESEARCH ACTIVITIES: (completed)

1	A091305: A Phase 2 Study Of Efatutazone, An Oral Ppar Agonist, In Combination With Paclitaxel In Patients With Advanced Anaplastic Thyroid Cancer. Role: PI
2	Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer. Role: Sub-I
3	UCCI-HN-1502: A Phase I/ II Study of chemo radiation plus the Anti-PD-1 Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma. Role: Sub-I
4	Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients with Advanced Solid Tumors and Recurrent High-Grade Gliomas.

TEACHING ACTIVITIES / LECTURES:

1	First line treatment options for patients with Mantle Cell Lymphoma <i>Bone marrow transplant center, UCMC</i>	2014
2	Cost effective analysis of treatment options for Brain tumor <i>Vontz Medical and Research Center, UCMC</i>	2014
3	Granulocyte Transfusion therapy in patients with prolonged neutropenia <i>Hoxworth blood center, Cincinnati</i>	2014
4	Bone Health and Cancer <i>Vontz Medical and Research Center, UCMC</i>	2014
5	The disease of Vampires: Porphyria and its treatment <i>Hoxworth blood center, Cincinnati</i>	2015
6	Uveal Melanoma, Clinical presentation, pathophysiology and treatment <i>Vontz Medical and Research Center, UCMC</i>	2015
7	Metastatic castrate resistant prostate cancer, treatment options <i>Vontz Medical and Research Center, UCMC</i>	2015
8	Post-Transplant Lymphoproliferative disorder, presentation & treatment <i>Bone marrow transplant center, UCMC</i>	2015

9	First line treatment of Follicular Lymphoma in young and elderly <i>Bone marrow transplant center, UCMC</i>	2015
10	Metastatic Breast Cancer: Crash Course <i>Hematology/Oncology conference</i>	2016
11	Bone Marrow Failure Syndromes <i>Hoxworth blood center, Cincinnati</i>	2016
12	Lymphoma in Pregnancy <i>Bone marrow transplant center, UCMC</i>	2016
13	Updates on Chronic myeloid and chronic lymphocytic leukemia <i>Nursing Oncology update, The Christ Hospital.</i>	2016
14	Management of Early Stage Breast Cancer <i>Vontz Medical and Research Center, UCMC</i>	2016
15	Metastatic Prostate Cancer, Research Conference <i>Research Symposium, UCMC</i>	2017
16	Soft Tissue Sarcoma of Extremity <i>Vontz Medical and Research Center, UCMC</i>	2017
17	Recurrent Head and Neck Cancer, Medicine Grand Rounds <i>Internal Medicine Department, UCMC</i>	2018
18	Metastatic Kidney Cancer <i>Core Curriculum to fellows, UCMC</i>	2018
19	Hormone sensitive and resistant Prostate Cancer <i>Core Curriculum to fellows, UCMC</i>	2019
20	Lung Cancer: South West Ohio Internal Medicine Course <i>SWOH conference</i>	2020

LICENSURE:

1	Ohio Medical Board
---	--------------------